Valuing a Pharmaceutical Asset: a new, data-rich tool for estimating a drug's true value (US)

October 11, 2018 | 1:00PM


With approval rates declining and clinical trial costs soaring, it’s difficult to accurately value a pharmaceutical product in development. Now there’s a new technology platform that aims to drive more accurate, data driven valuations. Pipeline Architect builds on IQVIA’s massive data sets on clinical trial timing, costs, revenues and success rates, to value an asset quickly and accurately. Whether you need to value a new business development or licensing deal, or determine the value of your own products in development, Pipeline Architect delivers best-in-class asset valuations.